Wyeth news from FierceBiotech
NewsPharmacopeia shares rise on blood pressure data
Pharmacopeia's shares were up today on trial results for PS433540, a hypertension drug. Data showed 'significant' blood pressure reductions in a Phase IIa study in patients with mild to moderate Read more...
SPOTLIGHT: Wyeth R&D chief exits with kudos for success
The blogsters at In Vivo have weighed in on the news that Wyeth R&D chief Bob Ruffolo is retiring. He may have been tough to get along with, but the blog gives Ruffolo credit for some Read more...
FDA approves Wyeth, Progenics drug
There's a big sigh of relief coming from Wyeth and Progenics today as the FDA approved Relistor, a subcutaneous injection for opioid-induced constipation in patients with advanced illness who are Read more...
Wyeth, Elan suspend Alzheimer's vaccine study
Wyeth and Elan have suspended dosing patients in a mid-stage study of the experimental Alzheimer's vaccine ACC-001 after seeing one of the patients in the study develop skin lesions. Studies of Read more...
Wyeth, ViroPharma drops Hep C drug
After observing serious safety problems in a Phase II trial, Wyeth and ViroPharma are dropping development of HCV-796. In August the companies halted study of the drug when the data showed elevated Read more...
ALSO NOTED: Ardana meets with potential suitors;Feds go back to basics with AIDS vax research; and much more...
> Ardana has provided an update on it's proposed sale or merger. The company says that it's met with a "significant number of interested parties," and that there is interest among it suitors Read more...
ALSO NOTED: Ipsen files new BLA;Amgen selects Vectibix test; and much more...
> Ipsen says it has submitted a new BLA for Reloxin, addressing concerns raised by the FDA when the agency declined to file its BLA in January. Read more...
Wyeth, Progenics drug flunks trial
Wyeth and Progenics were handed a serious blow today when their intravenous drug methylnaltrexone for postoperative ileus flunked the first of two Phase III trials. Initial results from the study Read more...
Wyeth dumps once-promising Curis collaboration
Back in 2004, Wyeth considered a project with Curis to develop small molecule and protein Hedgehog agonists--which promised new therapies for stroke and cardiovascular ailments--worth potentially Read more...
FDA OKs Wyeth's antidepressant Pristiq
Wyeth announced late Friday that it won FDA approval for Pristiq, its next-generation version of the antidepressant Effexor. Wyeth was looking for an approval of Pristiq to offset the Read more...
| Press ReleasesPRESS RELEASE: Raven biotechnologies and Wyeth Pharmaceuticals Extend Evaluation Period of Selected Raven Antibodies Raven biotechnologies and Wyeth Pharmaceuticals Extend Evaluation Period of Selected Raven Antibodies SOUTH SAN FRANCISCO, Calif., Dec. 6 -- Raven biotechnologies, inc., a privately held company Read more... PRESS RELEASE: Wyeth Consumer Healthcare Initiates Voluntary Recall and Replacement Program Wyeth Consumer Healthcare Initiates Voluntary Recall and Replacement Program for Several Robitussin Products and Children's Dimetapp Cold & Chest Congestion -- Dosage Cup Being Replaced, No Read more... PRESS RELEASE: Wyeth Jury Awards $99 Million Punitive Damages Wyeth Jury Awards $99 Million Punitive Damages MADISON, N.J., Oct. 15 -- Wyeth confirmed today that it will appeal the verdict in the Scofield, Rowatt and Forrester v. Wyeth cases in the Second Read more... PRESS RELEASE: Study Data Results Showed Desvenlafaxine Significantly Reduced Moderate to Severe Vasomotor Symptoms Study Data Results Showed Desvenlafaxine Significantly Reduced Moderate to Severe Vasomotor Symptoms in Menopausal Women Versus Placebo COLLEGEVILLE, Pa., Oct. 15 -- Wyeth Pharmaceuticals, a Read more... PRESS RELEASE: Wyeth Acquires Haptogen to Boost Biotechnology Drug Discovery Wyeth Acquires Haptogen to Boost Biotechnology Drug Discovery COLLEGEVILLE, Pa., Oct. 5 -- Wyeth Pharmaceuticals, a division of Wyeth, announced today the signing of a definitive agreement under Read more... |
Get more Wyeth coverage at:
Paid Research Reports
- Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
- Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
- Biotech 2008 – life sciences industry report (online & print)
- Is there a market for alcoholism pharmacotherapies?
- New report provides Rheumatoid Arthritis market insight